“A daily pill could soon be available as an alternative to Wegovy and Ozempic injections after a trial found it led to substantial weight loss and improved blood sugar levels in people with obesity and type 2 diabetes.

Orforglipron, developed by pharmaceutical company Eli Lilly, is designed to work in the same way as semaglutide, the active ingredient in Wegovy and Ozempic, which mimics a hormone called GLP-1.

A prior trial found that orforglipron enabled people with obesity but without type 2 diabetes to lose about 11 per cent of their body weight, on average, over 72 weeks. This is less than the 15 per cent typically achieved over a similar period with injectable semaglutide, but taking medication as a pill is more convenient, says Deborah Horn at the University of Texas.”

From New Scientist.